WO1995000852A3 - A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130 - Google Patents

A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130 Download PDF

Info

Publication number
WO1995000852A3
WO1995000852A3 PCT/IT1994/000095 IT9400095W WO9500852A3 WO 1995000852 A3 WO1995000852 A3 WO 1995000852A3 IT 9400095 W IT9400095 W IT 9400095W WO 9500852 A3 WO9500852 A3 WO 9500852A3
Authority
WO
WIPO (PCT)
Prior art keywords
superantagonists
site
antagonists
interleukin
receptor complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT1994/000095
Other languages
French (fr)
Other versions
WO1995000852A2 (en
Inventor
Rocco Savino
Armin Lahm
Gennaro Ciliberto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT94920582T priority Critical patent/ATE189528T1/en
Priority to DK94920582T priority patent/DK0656117T3/en
Priority to EP94920582A priority patent/EP0656117B1/en
Priority to CA002142973A priority patent/CA2142973C/en
Priority to HK98111980.2A priority patent/HK1011081B/en
Priority to DE69422893T priority patent/DE69422893T2/en
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority to AU71324/94A priority patent/AU687416B2/en
Publication of WO1995000852A2 publication Critical patent/WO1995000852A2/en
Publication of WO1995000852A3 publication Critical patent/WO1995000852A3/en
Anticipated expiration legal-status Critical
Priority to GR20000400800T priority patent/GR3033111T3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

It has been found that the ligands of the group of cytokins similar to Interleukin 6 (IL-6), that is Oncostatin M (OSM), Leukemia Inhibitory Factor (LIF), Ciliary Neurotrophic Factor (CNTF) and Interleukin 11 (IL-11), induce formation of a receptor complex of which the membrane molecule gp 130 is a part. It is thus possible to formulate the hypothesis that two different surfaces of the protein (in this class of hormones), known as site 1 and site 2, bind to two different molecules: site 1 to the specific receptor and site 2 to gp 130. The invention allows the identification of these sites and the isolation of variants having, with respect to the wild hormone, a greater affinity for the specific receptor (superagonists and superantagonists) or affinity for gp 130 reduced or abolished (antagonists and superantagonists). The figure shows the construct pHenΔ hIL-6 and the production of phasmidic particles that can be used to select agonists of Interleukin 6.
PCT/IT1994/000095 1993-06-23 1994-06-23 A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130 Ceased WO1995000852A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DK94920582T DK0656117T3 (en) 1993-06-23 1994-06-23 Method for selecting superagonists, antagonists and super antagonists for interleukin 6
EP94920582A EP0656117B1 (en) 1993-06-23 1994-06-23 A methodology for selecting superagonists, antagonists and superantagonists of interleukin 6
CA002142973A CA2142973C (en) 1993-06-23 1994-06-23 A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130
HK98111980.2A HK1011081B (en) 1993-06-23 1994-06-23 A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130
DE69422893T DE69422893T2 (en) 1993-06-23 1994-06-23 METHOD FOR SELECTING SUPERAGONISTS, ANTAGONISTS AND SUPERANTAGONISTS OF INTERLEUKIN 6
AT94920582T ATE189528T1 (en) 1993-06-23 1994-06-23 METHOD FOR SELECTING SUPERAGONISTS, ANTAGONISTS AND SUPERANTAGONISTS OF INTERLEUKIN 6
AU71324/94A AU687416B2 (en) 1993-06-23 1994-06-23 A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes GP 130
GR20000400800T GR3033111T3 (en) 1993-06-23 2000-03-29 A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM93A000409 1993-06-23
ITRM930409A IT1261787B (en) 1993-06-23 1993-06-23 METHODOLOGY FOR THE SELECTION OF SUPERAGONISTS, ANTAGONISTS AND SUPER-ANTAGONISTS OF HORMONES OF WHICH RECEPTOR COMPLEX IS PART OF GP 130.

Publications (2)

Publication Number Publication Date
WO1995000852A2 WO1995000852A2 (en) 1995-01-05
WO1995000852A3 true WO1995000852A3 (en) 1995-03-30

Family

ID=11401818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1994/000095 Ceased WO1995000852A2 (en) 1993-06-23 1994-06-23 A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130

Country Status (13)

Country Link
EP (1) EP0656117B1 (en)
JP (1) JP2643604B2 (en)
CN (2) CN1249439C (en)
AT (1) ATE189528T1 (en)
AU (1) AU687416B2 (en)
CA (1) CA2142973C (en)
DE (1) DE69422893T2 (en)
DK (1) DK0656117T3 (en)
ES (1) ES2144524T3 (en)
GR (1) GR3033111T3 (en)
IT (1) IT1261787B (en)
PT (1) PT656117E (en)
WO (1) WO1995000852A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1276555B1 (en) * 1995-04-28 1997-11-03 Angeletti P Ist Richerche Bio HUMAN INTERLUCHINA-6 ANTAGONISTS COMPLETELY UNABLE TO FORM A BOND WITH GP 130, AND USE THEM FOR THE PREPARATION OF COMPOSITIONS
IT1277926B1 (en) * 1995-09-01 1997-11-12 Angeletti P Ist Richerche Bio USE OF NATURAL CYTOKINE MUTEINS AS IMMUNOGENS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TO TREAT OR PREVENT
US5849293A (en) * 1996-01-11 1998-12-15 Cornell Research Foundation, Inc. Use of human transferrin in controlling insulin levels
IT1285790B1 (en) * 1996-09-24 1998-06-24 Angeletti P Ist Richerche Bio ADENOVIRUS RECOMBINANT DEFECTIVES CODING FOR MUTANTS OF HUMAN INTERLEUKINE 6 (HIL-6) WITH ANTAGONIST ACTIVITY OR
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
YU29804A (en) * 2001-10-11 2006-08-17 Applied Research Systems Ars Holding N.V. USE OF gp 130 ACTIVATORS IN DIABETIC NEUROPATHY
FR2833011B1 (en) * 2001-12-04 2004-10-29 Univ Claude Bernard Lyon NOVEL PROTEIN WITH IL-6 INHIBITING ACTIVITY
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
CN101246160B (en) * 2007-09-06 2012-11-21 三峡大学 IL-6/sIL-6R combined molecular model established by ELISA method in vitro
DE102011104822A1 (en) * 2011-06-18 2012-12-20 Christian-Albrechts-Universität Zu Kiel Ciliary Neutrophic factor variants
JP6280031B2 (en) 2012-03-29 2018-02-14 中外製薬株式会社 Anti-LAMP5 antibody and use thereof
HUE065402T2 (en) * 2017-08-11 2024-05-28 Solvay Specialty Polymers It Method for stabilizing aqueous dispersions of fluorinated polymers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004788A1 (en) * 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
EP0411946A2 (en) * 1989-08-03 1991-02-06 Tadamitsu Kishimoto DNA encoding human GP130 protein
WO1992021029A1 (en) * 1991-05-10 1992-11-26 Genentech, Inc. Selecting ligand agonists and antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2898040B2 (en) * 1990-01-26 1999-05-31 忠三 岸本 Antibodies to gp130 protein
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
CA2147466A1 (en) * 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
EP0749980A4 (en) * 1993-12-29 1999-09-29 Sumitomo Pharma NEW HUMAN CILIARY NEUROTROPHIC FACTOR

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004788A1 (en) * 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
EP0411946A2 (en) * 1989-08-03 1991-02-06 Tadamitsu Kishimoto DNA encoding human GP130 protein
WO1992021029A1 (en) * 1991-05-10 1992-11-26 Genentech, Inc. Selecting ligand agonists and antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp 130 activation", EMBO JOURNAL, vol. 13, no. 6, 1994, HEIDELBERG FRG, pages 1357 - 1367 *

Also Published As

Publication number Publication date
AU687416B2 (en) 1998-02-26
HK1011081A1 (en) 1999-07-02
WO1995000852A2 (en) 1995-01-05
ES2144524T3 (en) 2000-06-16
DE69422893T2 (en) 2000-08-17
DE69422893D1 (en) 2000-03-09
EP0656117A1 (en) 1995-06-07
DK0656117T3 (en) 2000-07-24
CA2142973C (en) 2004-10-26
GR3033111T3 (en) 2000-08-31
CN1112795A (en) 1995-11-29
JP2643604B2 (en) 1997-08-20
ITRM930409A1 (en) 1994-12-23
ITRM930409A0 (en) 1993-06-23
IT1261787B (en) 1996-06-03
CN1538176A (en) 2004-10-20
CN1249439C (en) 2006-04-05
CN1101937C (en) 2003-02-19
CA2142973A1 (en) 1995-01-05
ATE189528T1 (en) 2000-02-15
JPH07509571A (en) 1995-10-19
PT656117E (en) 2000-07-31
EP0656117B1 (en) 2000-02-02
AU7132494A (en) 1995-01-17

Similar Documents

Publication Publication Date Title
WO1995000852A3 (en) A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130
PT745094E (en) SUPERAGONISTS AND ANTAGONISTS OF HUMAN IL-6 AND METHOD FOR THEIR SELECTION
CA2275489A1 (en) Oil bodies and associated proteins as affinity matrices
Schroers et al. Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane
CA2124085A1 (en) Receptor for Oncostatin M and Leukemia Inhibitory Factor
TW366364B (en) Optimization of binding proteins
WO1995033059A3 (en) Receptor for oncostatin m
ATE177147T1 (en) MAMMAL RECEPTORS FOR INTERLEUKIN 10 (IL-10)
ATE449850T1 (en) MUTANTS OF FLT3-L AND THEIR USES
WO2002102854A3 (en) Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP2290079A3 (en) Neurotrophic factors
EP1231265A3 (en) A receptor protein tyrosine kinase
DE3855536D1 (en) RECEPTORS FOR GROWTH HORMONES
ATE272116T1 (en) POLYPEPTIDES WITH THE POSSIBILITY OF FORMING RHESUS D ANTIGEN-SPECIFIC BINDING STRUCTURES, THE DNA CODING FOR THEM AND THE PROCESS OF PRODUCTION AND USE
EP0628054A4 (en) CAR RECEPTORS, RELATED MOLECULES AND METHODS OF OBTAINING SAME.
CA2133554A1 (en) Synthesis of diverse and useful collections of oligonucleotides
DK0901379T3 (en) Type 2 chemokine binding proteins and methods for their use
WO1995027060A3 (en) Biologically active eph family ligands
EP0239311A3 (en) Mutual separation of proteins
WO1992016623A3 (en) Receptors for bombesin-like peptides
ATE281519T1 (en) CLONING AND RECOMBINANT PRODUCTION OF THE CRF RECEPTOR (CRF=CORTICOTROPIN RELEASING FACTOR)
DK0914451T3 (en) IL-1 / TNF-alpha-activated kinase (ITAK) and methods of preparation and use thereof
WO2001066598A3 (en) Chemoattractant receptor characterization and cell selection materials and methods and chemokine receptor ccr11 materials and methods
WO1995035376A3 (en) Polypeptides with interleukin 8 receptor 1 (il8r1) binding domains
DE69635667D1 (en) BIOLOGICALLY ACTIVE LIGANDS OF THE EPH FAMILY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1994920582

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2142973

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1995 387924

Country of ref document: US

Date of ref document: 19950223

Kind code of ref document: A

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1994920582

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994920582

Country of ref document: EP